Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study

W. Flinn, Ian; van der Jagt, Richard; S. Kahl, Brad; Wood, Peter; E. Hawkins, Tim; MacDonald, David; Hertzberg, Mark; Kwan, Yiu‐Lam; Simpson, David; Craig, Michael; S. Kolibaba, Kathryn; Issa, Samar; Clementi, Regina; M. Hallman, Doreen; Munteanu, Mihaela; Chen, Ling; M. Burke, John

doi:10.1182/blood-2013-11-531327

Public

Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study

Published in Blood • Mar 4, 2014

Authors:

Ian W. Flinn

Richard van der Jagt

Brad S. Kahl

Abstract

This randomized, noninferiority (NI), global, phase 3 study evaluated the efficacy and safety of bendamustine plus rituximab (BR) vs a standard rituximab-chemotherapy regimen (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone [R-CHOP] or rituximab plus cyclophosphamide, vincr...

Subject

Bendamustine

Rituximab

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!